A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis (AMETRINE-SC)
A Phase III, Multicenter, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Учебное резервное копирование контактов
- Имя: Reference Study ID Number: CA46523 https://forpatients.roche.com/ No attachments to email below.
- Номер телефона: 888-662-6728 (U.S. and Canada)
- Электронная почта: global-roche-genentech-trials@gene.com
Места учебы
-
-
Tennessee
-
Cordova, Tennessee, Соединенные Штаты, 38018
- Рекрутинг
- Gastro One
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Confirmed diagnosis of UC.
- Moderately to severely active UC assessed by modified Mayo Score (mMS).
- Bodyweight >= 40 kilogram (kg).
- Up to date with colorectal cancer (CRC) screening performed according to local standards.
- Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced UC therapy.
- Females of childbearing potential must meet protocol criteria for contraception requirements.
Exclusion Criteria:
- Currently known complications of UC (e.g. fulminant colitis, toxic megacolon).
- Current diagnosis of Crohn's disease (CD) or indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis.
- Presence of an ostomy or ileoanal pouch.
- Current diagnosis or suspicion of primary sclerosing cholangitis.
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study.
- Past or current evidence of definite low-grade or high-grade colonic dysplasia or adenomas or neoplasia not completely removed.
- History of malignancy within 5 years, with the exception of malignancies adequately treated with resection for non-metastatic basal cell or squamous cell cancer or in situ cervical cancer.
- Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV).
- Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB.
- Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Afimkibart
Participants will receive afimkibart administered as subcutaneous (SC) injection. |
Afimkibart will be administered as SC injection.
Другие имена:
|
|
Плацебо Компаратор: Placebo
Participants will receive placebo adminsitered as SC injection. |
Placebo will be administered as SC injection. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Percentage of Participants With Clinical Remission
Временное ограничение: At Week 12
|
At Week 12
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change From Baseline in Stool Frequency Subscore (SFS)
Временное ограничение: From Baseline up to Week 12
|
The Stool Frequency Subscore (SFS) is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal) |
From Baseline up to Week 12
|
|
Change From Baseline in Rectal Bleeding Subscore (RBS)
Временное ограничение: From Baseline up to Week 12
|
The Rectal Bleeding Subscore (RBS) is measured on a scale from 0 (no blood seen) to 3 (blood alone passed) |
From Baseline up to Week 12
|
|
Percentage of Participants With Symptomatic Response
Временное ограничение: At Week 4
|
At Week 4
|
|
|
Percentage of Participants With Endoscopic Improvement
Временное ограничение: At Week 12 and Week 24
|
At Week 12 and Week 24
|
|
|
Percentage of Participants With Endoscopic Remission
Временное ограничение: At Week 12 and Week 24
|
At Week 12 and Week 24
|
|
|
Percentage of Participants With Clinical Response
Временное ограничение: At Week 12
|
At Week 12
|
|
|
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement
Временное ограничение: At Week 12 and Week 24
|
At Week 12 and Week 24
|
|
|
Percentage of Participants With Clinical Remission
Временное ограничение: At Week 24
|
At Week 24
|
|
|
Percentage of Participants With Maintenance of Remission
Временное ограничение: At Week 12 and Week 24
|
At Week 12 and Week 24
|
|
|
Percentage of Participants With Histologic Improvement
Временное ограничение: At Week 24
|
At Week 24
|
|
|
Change From Baseline in Bowel Urgency
Временное ограничение: From Baseline through Week 12 and Week 24
|
Bowel urgency will be assessed using two self-reported items over the past 24 hours: presence of bowel urgency (Yes/No) and severity on an 11-point numerical rating scale from 0 (no urgency) to 10 (worst possible urgency) |
From Baseline through Week 12 and Week 24
|
|
Change From Baseline in Abdominal Pain
Временное ограничение: From Baseline through Week 12 and Week 24
|
Abdominal pain will be assessed using two self-reported items over the past 24 hours: presence of abdominal pain (Yes/No) and severity on an 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain) |
From Baseline through Week 12 and Week 24
|
|
Change From Baseline in Fatigue
Временное ограничение: From Baseline through Week 12 and Week 24
|
Change in fatigue will be assessed by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. FACIT-Fatigue is a 13-item self-reported assessment of the level and impact of fatigue. The overall FACIT-Fatigue score ranges between 0 and 52, with higher scores associated with better quality of life concerns related to fatigue |
From Baseline through Week 12 and Week 24
|
|
Change From Baseline in Health-Related Quality of Life
Временное ограничение: From Baseline through Week 12 and Week 24
|
Change in health-related quality of life will be assessed by Inflammatory Bowel Disease Questionnaire (IBDQ) score. IBDQ is a 32-item self-reported assessment of health-related quality of life in participants with inflammatory bowel disease. The overall IBDQ score ranges from 32 to 224, with higher scores associated with better health-related quality of life |
From Baseline through Week 12 and Week 24
|
|
Change From Baseline in Overall UC Symptoms
Временное ограничение: Baseline, Week 2, Week 12 and Week 24
|
Change in overall UC symptoms will be assessed by Patient Global Impression of Change (PGIC). PGIC measures overall change in ulcerative colitis symptoms from "Much better" to "Much worse" |
Baseline, Week 2, Week 12 and Week 24
|
|
Change From Baseline in Overall Severity in UC Symptoms
Временное ограничение: Baseline, Week 2, Week 12 and Week 24
|
Change in overall severity of UC symptoms will be assessed by Patient Global Impression of Severity (PGIS). PGIS measures severity of ulcerative colitis symptoms from "None" to "Very severe" |
Baseline, Week 2, Week 12 and Week 24
|
|
Incidence and Severity of Adverse Events (AEs)
Временное ограничение: From Baseline up to approximately 42 Weeks
|
From Baseline up to approximately 42 Weeks
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Trials, Hoffmann-La Roche
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- CA46523
- 2026-526684-37-00 (Ктис)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .